anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An arteriovenous fistula (AVF) is the optimal vascular access for chronic hemodialysis. However, AVFs frequently fail to mature. Better strategies are needed to promote AVF maturation. Successful AVF maturation involves arterial and venous dilation. Arterial dilation depends on endothelial release of nitric oxide which can be measured by brachial artery flow-mediated dilation (FMD) and has been reported to predict successful AVF maturation. Venous dilation depends on venous compliance which can be measured by venous plethysmography and is also predictive of successful AVF maturation. Endothelial function is impaired in patients with chronic kidney disease (CKD). Aerobic exercise has been reported to improve endothelial function and venous compliance but it has not been studied in the pre-dialysis patient. To address this question we will determine whether 6 weeks of repetitive handgrip exercise with upper arm venous compression can improve brachial artery endothelial function or venous compliance in pre-dialysis patients with an estimated glomerular filtration rate of less than or equal to 20 ml/min.
The invention provides a drug delivery device for latanoprost or latanoprost acid. The device has a core of latanoprost or latanoprost acid which is surrounded by an internal and external sheath. The external sheath has a first cap that is permeable to latanoprost or latanoprost acid. The first cap may comprise polyvinyl alcohol (PVA), and the PVA may be heat cured. In certain aspects, there are one or more additional caps on the ends of the sheaths formed from one or more polymers. In certain aspects, one or more portions of the drug delivery device is substantially impermeable to latanoprost or latanoprost acid. In certain aspects, the latanoprost or latanoprost acid elutes through the first cap into a biological environment. The invention further provides methods for manufacturing the drug delivery device.
A computer implemented personalized health record system and method is envisaged. The system provides smart cards to profile registrants on registration, which are associated with the profile registrants' health records and have a unique identification number corresponding to every profile registrant. The system stores profile registrants' information along with their health records and demographic information and associates it with their corresponding unique identification numbers. The demographic information can be edited/updated by a profile registrant on successful authentication. When a profile registrant visits a health facility/laboratory, after successful two level authentications, an authenticated health registrant is able to access health records of the authenticated profile registrant and medical history along with profile registrant's demographic information in order to provide a better diagnosis/treatment. Any treatment details after the diagnosis and/or prescription provided by the physician and the test results from the laboratory are then updated in the system through a network.
The hallux valgus surgery is often characterized by a significant post-operative pain difficult to control with oral analgesics. Consequently, large doses of parenteral opioids are often required Various nerve blocks (popliteal, saphenous, sciatic) can give excellent post-operative pain control. Among loco-regional anesthesia techniques, the sciatic nerve block provides good post-operative pain relief after foot surgery. Thus, sciatic nerve block with long-acting local anesthetics (with or without a peri-neural catheter) has been recommended as a primary option. This analgesic approach should cause a difficult discharge in ambulatory and one-day surgery patients, due to the prolonged motor recovery and loss of proprioception and protective pain reflexes. Therefore, it would be preferable to use the sciatic nerve block just for intra- operative anesthesia without affecting motor recovery, and to apply multimodal analgesia for post- operative pain management. Hallux valgus repair can now be done percutaneously, a minimally invasive technique called ''mini-invasive hallux valgus repair'', consisting in osteotomies through 3 to 5 mm incisions, without internal fixation. This approach requires less dissection and exposure, determining a smaller inflammatory response and theoretically causing less pain. Ideal anesthesia for these procedures should provide rapid patient recovery, minimal nursing care requirements in the post- anesthesia care unit and an earlier hospital discharge. It must provide effective analgesia, since the foot surgery is known to induce a moderate-to- severe post-operative pain, that represents one of the major limitations to hospital discharge on the day of surgery and is the main cause of re-admission.

The aim of this matched-control study was to evaluate two different techniques of post-operative analgesia after hallux valgus correction in one-day surgery patients.
Subjects in this group did not receive an intervention. They filled out measures at baseline, 1 month, and 3 month follow-up time periods.
A planning image memory (14) stores a volume diagnostic image. A user inputs data defining clinical objectives including organs-at-risk with a user interface device (32). An auto-planning module (36) generates a candidate treatment plan. A trade- off module (38) having a processor evaluates the treatment plan against the clinical objectives. When one or more objectives is not met, the trade-off module (38) performs a trade-off analysis to determine an effect on other clinical objectives and generates at least one trade-off treatment plan which more closely meets the not met objectives. The candidate and at least one trade-off plan are displayed on a display device (30) and/or analyzed by the processor and a final treatment plan is selected from the at least one trade-off or candidate treatment plan.
A computer-implemented method, data processor and computer program product determine exposure levels to external stimuli. At least one environmental condition is monitored and an external stimulus event is identified based on the at least one environmental condition. An intensity level of the external stimulus event is determined to exceed a predetermined threshold. An exposure level of the external stimulus is determined by integrating the intensity level over time. At least one human biometric quantity of a user is measured and a personal exposure level limitation is determined for the user based on the measured at least one human biometric quantity. When the exposure level exceeds the personal exposure level limitation, the user is warned of the exposure level. The human biometric quantity is one of: heart rate, blood pressure, body temperature, glucose level, blood oxygen level, muscle activity, electrolyte level, and lactic acid level.
The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, the present invention provides compositions and methods for the use of one or more cas genes or proteins for modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In additional embodiments, the present invention provides methods for labelling and/or identifying bacteria. In some preferred embodiments, the present invention provides methods for the use of CRISPR loci to determine the potential virulence of a phage against a cell and the use of CRISPR-cas to modulate the genetic sequence of a phage for increased virulence level. In still further embodiments, the present invention provides means and compositions for the development and use of phages as biocontrol agents.
<P>PROBLEM TO BE SOLVED: To obtain a lubricant composition which is used for tablets, exhibits good tabletting moldability, and can give the tablets having high tablet hardness and good collapsibility.  <P>SOLUTION: This lubricant composition used for the tablets, comprising sucrose fatty acid esters and a 16 to 22C fatty acid salt, is characterized in that the sucrose fatty acid esters comprises 20 to 50 wt. % of a sucrose fatty acid ester having an esterification degree of 1 to 3, 30 to 60 wt. % of a sucrose fatty acid ester having an esterification degree of 4 to 6, and ≤20 wt. % of a sucrose fatty acid ester having an esterification degree of 7 to 8.  <P>COPYRIGHT: (C)2004,JPO
This will be a single-cohort Phase II single center, prospective trial. Patients with stage IV NSCLC are eligible. Patients may receive standard of care systemic therapy (chemotherapy and/or immunotherapy). Radiotherapy will be directed at high-risk disease (primary cancer, nodal metastases, and metastases) in the thorax. Treatment of other sites of extrathoracic metastases would be allowed as per standard of care. Standard chest radiation dosing and normal tissue exposures (based on published or ongoing studies) will be applied. There is no plan to escalate the chest radiation dose (i.e., no Phase I component) as palliative regimens for NSCLC have been routinely used for many decades.
Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 1 (Non Rebreathing Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
###  Risk Summary

CARDURA XL is not indicated for use in females and is not indicated for the treatment of hypertension. The limited available data with CARDURA XL in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. No adverse developmental outcomes were observed in animal reproduction studies with oral administration of doxazosin to pregnant rats and rabbits at doses of up to 10 and 4 times, respectively, the 12 mg/day recommended dose. Postnatal development was delayed in rats at a dose of 8 times the 12 mg/day recommended dose [see Data]. 

###  Data

#### Animal Data 

Radioactivity was found to cross the placenta following oral administration of labeled doxazosin to pregnant rats. Studies in pregnant rabbits and rats at daily oral doses of up to 41 and 20 mg/kg, respectively (plasma drug concentrations of 10 and 4 times, respectively, the human AUC exposures with a 12 mg/day therapeutic dose), during organogenesis have revealed no evidence of adverse developmental effects. A dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival. In peri- and postnatal studies in rats, postnatal development at maternal doses of 40 or 50 mg/kg/day of doxazosin (about 8 times human AUC exposure with a 12 mg/day therapeutic dose) was delayed, as evidenced by slower body weight gain and slightly later appearance of anatomical features and reflexes.
BACKGROUND: The risk of anal cancer is increased in patients with human immunodeficiency virus (HIV), inflammatory bowel disease (IBD), and among men who have sex with men (MSM). High grade squamous intraepithelial lesions (HSILs) are precursor lesions to anal squamous cell carcinoma (SCC), and treatment of these lesions can decrease progression to anal SCC. This study aims to determine the prevalence of HSIL and anal cancer among MSM patients with and without IBD referred for anal cancer screening.
METHODS: This is a retrospective study of all MSM patients seen at an anal squamous intraepithelial lesions (aSILs) and anal cancer screening specialty clinic. Data were manually and electronically collected from clinical documentation and pathology results for the primary outcomes of HSIL and anal cancer. Demographics, HIV status, IBD disease status, disease phenotype, and immunosuppressive medication use were collected through the electronic health record. Descriptive statistics were used.
RESULTS: In all, 4623 patients were included for analysis. Among 57 MSM patients with IBD, 25 (43.9%) had a history of HSIL, and 2 (3.5%) had a history of anal cancer. Among 4618 MSM patients without IBD, 2417 (52.3%) had a history of HSIL, and 139 (3.0%) had a history of anal cancer (P = .744). Rates of HIV were 49.1% among MSM patients with IBD and 69.8% among MSM patients without IBD (P = .001). There remained no difference in prevalence of HSIL and anal cancer between groups when adjusting for HIV status. Among IBD patients, only 21.6% were referred for screening by their gastroenterologist.
CONCLUSIONS: Among MSM with and without IBD, both groups had an equally high prevalence of HSIL and anal SCC. Awareness of appropriate surveillance to identify aSIL in MSM patients with IBD is needed among gastroenterologists.
Traditional hemostatic hydrogels face considerable limitations in achieving rapid control of severe bleedings, a crucial factor in reducing casualties in both military and civilian settings. This study presents a chitosan-based hemostatic hydrogel with interconnected secondary macropores designed to enhance interactions with blood clotting components by reducing diffusion resistance and increasing contact area. The macropores were created using a straightforward process involving NaOH-mediated SiO2 template dissolution and NH3 generation. The resulting macroporous structure increased the hydrogel's overall porosity without compromising its viscoelasticity. Functional studies demonstrated that the macroporous hydrogel effectively concentrated and adsorbed blood clotting components, while also facilitating the delivery of artificially embedded clotting factor to further expedite clot formation. These combined actions resulted in improve hemostatic efficacy, reducing whole blood clotting time by over 94 % in vitro. Furthermore, in vivo studies using rat tail amputation and liver injury models showed a reduction in blood loss by over 65 % and a decrease in bleeding time by over 70 %. Additionally, the porous chitosan hydrogel exhibited minimal biotoxicity and promoted biodegradability in vivo. In conclusion, this work introduces a macroporous chitosan-based hemostatic hydrogel with great potential for rapid hemorrhage control.
BACKGROUND: Clowning has been used in many hospitals, particularly for children. Studies suggest the effectiveness of this methodology, but more evidence is needed. The aim of this study was to evaluate the impact of a humour therapy intervention on biological markers, pain and anxiety levels in paediatric patients.
METHODS: Three different clinical contexts were chosen to assess the effect of clowning interventions: patients who were subjected to venepuncture (group 1), patients undergoing general anesthesia for any cause (group 2)and patients hospitalized in the pediatric ward without distinction of their disease (group 3). Groups 1 and 2 were divided into control (C) and intervention (I) subgroups. A saliva sample was taken from all the children to measure oxytocin and cortisol levels by ELISAs. Validated scales and crying time were used to determine pain, stress, and anxiety levels. Children in group 3 were assessed before and after the intervention, employing the same methods.
RESULTS: A total of 272 patients were included. The children in group 1 (n = 125) were 7.7 ± 3.2 years old, and 53.6% were females. 48% were in the I group, which showed decreased cortisol levels and increased oxytocin levels. The I group exhibited a decrease in perceived pain and crying time. The children in group 2 (n = 69) were aged 7.1 ± 3.5 years, and 36% were females. 51% were in the I group, which showed increased oxytocin levels and decreased cortisol levels, acute stress levels, perceived pain, and crying time. The children in group 3 (n = 78) were 8.6 ± 3.3 years old, and 54% of the children were females. There was an increase in oxytocin levels and a decrease in cortisol levels, stress levels and perceived pain following the intervention.
CONCLUSIONS: This study suggested that an intervention based on clowning is an effective strategy for decreasing pain, stress, and anxiety levels in paediatric patients in different clinical contexts. These findings support the implementation of humour therapy programs in paediatric units.
Preeclampsia, a pregnancy complication characterized by hypertension after 20 gestational weeks, is a major cause of maternal and neonatal morbidity and mortality. Mechanisms leading to preeclampsia are unclear; however, there is evidence of high heritability. We evaluated the association of polygenic scores (PGS) for blood pressure traits and preeclampsia to assess whether there is shared genetic architecture. Non-Hispanic Black and White reproductive age females with pregnancy indications and genotypes were obtained from Vanderbilt University's BioVU, Electronic Medical Records and Genomics network, and Penn Medicine Biobank. Preeclampsia was defined by ICD codes. Summary statistics for diastolic blood pressure (DBP), systolic blood pressure (SBP), and pulse pressure (PP) PGS were acquired from Giri et al. Associations between preeclampsia and each PGS were evaluated separately by race and data source before subsequent meta-analysis. Ten-fold cross validation was used for prediction modeling. In 3504 Black and 5009 White included individuals, the rate of preeclampsia was 15.49%. In cross-ancestry meta-analysis, all PGSs were associated with preeclampsia (ORDBP = 1.10, 95% CI 1.02-1.17, p = 7.68 × 10-3; ORSBP = 1.16, 95% CI 1.09-1.23, p = 2.23 × 10-6; ORPP = 1.14, 95% CI 1.07-1.27, p = 9.86 × 10-5). Addition of PGSs to clinical prediction models did not improve predictive performance. Genetic factors contributing to blood pressure regulation in the general population also predispose to preeclampsia.
Biodegradable cellulose photoacoustic probes are provided that are able to detect biological targets and generate a detectable photoacoustic signal. The cellulose nanoparticles are biodegradable by cellulases. Clearance of the nanoparticles from a subject is enhanced and results in improved contrast of a photoacoustic-generated image. Methods to generate images by administering a cellulose nanoparticle probes to a subject and irradiating with light of a wavelength to emit photoacoustic energy detectable by sensors external to the subject are also provided. The detectable signal is convertible to a visual image of the nanoparticle probes in the subject. The methods may include allowing a cellulase to degrade nanoparticles so that undesirable background signals emitted are substantially reduced to increase the contrast and quality of the generated image. In the absence of an endogenous source of an enzyme for degrading the cellulose nanoparticles, a composition comprising a heterologous cellulase may be administered along with the nanoparticles.
The use of des(B25-30) hexapeptide insulin or a corresponding insulin B24 amide substd. on the amide N-atom by a residue R (R being 1-6C alkyl opt. omega-substd. by a phenyl group) as a medicament for the selective treatment of type II diabetes mellitus by lowering blood glucose concn. without substantial stimulation of glucose uptake into fatty tissue is new. Medicaments consisting of des-(B25-30) hexapeptide insulin or a corresponding insulin B24 amide substd. on the amide N-atom by a residue R, together with usual pharmaceutical additives, diluents and/or solvents are new. USE - The specified insulin B24 derivs. stimulate muscular glucose up take and lower blood glucose levels in the same way as insulin, but unlike insulin have a substantially reduced stimulant effect on glucose uptake in fatty tissue, and are therefore of use in the selective treatment of type II diabetes mellitus.
The invention discloses an effect of inhibiting tumor of CD226 extracellular domain protein. The CD226 extracellular domain protein is a protein consisting of an amino acid sequence shown by SEQ ID NO:1. The protein disclosed by the invention can be combined with CD112 and CD155, can be used for effectively closing binding sites between CD226 and target cells and inhibiting the cellular poison activity of NK cells, can be used as an inhibitor of the NK cells for treating autoimmune diseases on the one hand, and can generate an inhibitory action on proliferation of tumor cells after being combined with CD112 or CD155 molecules on the surfaces of the tumor cells on the other hand. Therefore, the protein can be used for inhibiting the proliferation of tumors in a tumor patient with a low immunologic function. Moreover, because the protein is a human body natural protein, an immunologic reaction of an organism is rarely caused. The invention relates to application of the CD226 extracellular domain protein in preparation of medicaments for inhibiting tumor cell proliferation.
OBJECTIVE: Fibroadenomas (FAs) involved by atypia are rare. Consensus guidelines for management of FAs involved by atypia when diagnosed on image-guided biopsy do not exist because of limited data reporting surgical upgrade rates to ductal carcinoma in situ (DCIS) or invasive malignancy. Therefore, these lesions commonly undergo surgical excision.
METHODS: This single-institution retrospective study identified cases of FAs involved by atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and/or lobular carcinoma in situ (LCIS) diagnosed on image-guided biopsy between January 2014 and April 2023 to determine upgrade rates. Cases with incidental atypia adjacent to but not involving FAs were excluded.
RESULTS: Among 1736 FAs diagnosed on image-guided biopsy, 32 cases (1.8%) were FAs involved by atypia including 43.8% (14/32) ALH, 28.1% (9/32) ADH, 18.8% (6/32) LCIS, 6.3% (2/32) LCIS + ALH, and 3.1% (1/32) unspecified atypia. The most common imaging finding was a mass. Most cases, 81.3% (26/32), underwent subsequent surgical excisional biopsy. A single case of ADH involving and adjacent to an FA was upgraded to FA involved by low-grade DCIS on excision for an overall surgical upgrade rate of 3.8%. There were no cases upgraded to invasive malignancy. For those omitting surgical excision, there was no subsequent malignancy diagnosis at the FA biopsy site over a mean follow-up of 73 months.
CONCLUSION: Cases of radiologic-pathologic concordant FAs involved by atypia have a low upgrade rate of 3.8% and should undergo multidisciplinary review. Larger multi-institutional analysis is needed to determine whether guidelines for excision of atypia should apply to atypia involving FAs.
Some patients given selegiline may experience an exacerbation of levodopa associated side effects, presumably due to the increased amounts of dopamine reaction with super sensitive, post-synaptic receptors. These effects may often be mitigated by reducing the dose of levodopa/carbidopa by approximately 10 to 30%.

The decision to prescribe selegiline should take into consideration that the MAO system of enzymes is complex and incompletely understood and there is only a limited amount of carefully documented clinical experience with selegiline. Consequently, the full spectrum of possible responses to selegiline may not have been observed in pre-marketing evaluation of the drug. It is advisable, therefore, to observe patients closely for atypical responses.

###  Melanoma

Epidemiological studies have shown that patients with Parkinson's disease have a higher risk (2-to approximately 6-fold higher) of developing melanoma than the general population. Whether the increased risk observed was due to Parkinson's disease or other factors, such as drugs used to treat Parkinson's disease, is unclear. For the reasons stated above, patients and providers are advised to monitor for melanomas frequently and on a regular basis when using selegiline for any indication. Ideally, periodic skin examinations should be performed by appropriately qualified individuals (e.g., dermatologists).